Article Details
Retrieved on: 2022-08-04 06:49:28
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... followed a $2 billion alliance – including $300 million paid upfront – with Adaptive Biotech focusing on TCR therapies for solid tumours.
Article found on: pharmaphorum.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here